Scarica l'app Stockscreener
2.765
1.58%
-0.075
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GDRX Giù?
Forum
Previsione
Precedente Chiudi:
$2.84
Aprire:
$2.8
Volume 24 ore:
570.56K
Relative Volume:
0.22
Capitalizzazione di mercato:
$934.74M
Reddito:
$796.85M
Utile/perdita netta:
$30.44M
Rapporto P/E:
32.84
EPS:
0.0842
Flusso di cassa netto:
$93.88M
1 W Prestazione:
+9.61%
1M Prestazione:
+30.61%
6M Prestazione:
-10.13%
1 anno Prestazione:
-34.08%
Intervallo 1D:
$2.72
$2.88
Intervallo di 1 settimana:
$2.44
$2.88
Portata 52W:
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
Nome
Goodrx Holdings Inc
Settore
Industria
Telefono
(855) 268-2822
Indirizzo
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, BTSG, TEM, HQY, DOCS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
2.76 | 961.84M | 796.85M | 30.44M | 93.88M | 0.0842 |
VEEV
Veeva Systems Inc
|
165.86 | 27.46B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
54.03 | 10.27B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
47.05 | 8.88B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
83.33 | 7.10B | 1.31B | 215.20M | 408.32M | 2.4627 |
DOCS
Doximity Inc
|
25.54 | 4.81B | 637.78M | 239.40M | 307.21M | 1.1909 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-27 | Downgrade | JP Morgan | Overweight → Neutral |
| 2026-01-22 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-09 | Iniziato | Barclays | Underweight |
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Iniziato | Mizuho | Neutral |
| 2024-08-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-01-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-08-10 | Aggiornamento | DA Davidson | Neutral → Buy |
| 2023-07-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Iniziato | Citigroup | Buy |
| 2022-11-04 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-08-12 | Iniziato | DA Davidson | Neutral |
| 2022-06-10 | Downgrade | Goldman | Buy → Neutral |
| 2022-06-06 | Ripresa | BofA Securities | Buy |
| 2022-06-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Iniziato | Wells Fargo | Equal Weight |
| 2022-04-07 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Neutral |
| 2022-03-15 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Reiterato | Barclays | Overweight |
| 2022-03-01 | Reiterato | BofA Securities | Neutral |
| 2022-03-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-01 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Reiterato | Evercore ISI | Outperform |
| 2022-03-01 | Reiterato | Goldman | Buy |
| 2022-03-01 | Reiterato | JP Morgan | Underweight |
| 2022-03-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-03-01 | Reiterato | SVB Leerink | Outperform |
| 2022-01-07 | Iniziato | Goldman | Buy |
| 2021-12-21 | Iniziato | Stephens | Overweight |
| 2021-12-02 | Iniziato | Jefferies | Buy |
| 2021-08-31 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Iniziato | Robert W. Baird | Neutral |
| 2021-04-06 | Ripresa | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Guggenheim | Buy |
| 2020-11-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Iniziato | Barclays | Equal Weight |
| 2020-10-19 | Iniziato | BofA Securities | Neutral |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-19 | Iniziato | Cowen | Outperform |
| 2020-10-19 | Iniziato | Credit Suisse | Outperform |
| 2020-10-19 | Iniziato | Deutsche Bank | Hold |
| 2020-10-19 | Iniziato | Goldman | Neutral |
| 2020-10-19 | Iniziato | JP Morgan | Neutral |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
| 2020-10-19 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Iniziato | SVB Leerink | Outperform |
| 2020-10-19 | Iniziato | UBS | Buy |
Mostra tutto
Goodrx Holdings Inc Borsa (GDRX) Ultime notizie
GoodRx (GDRX) Reports Strong Q1 2026 Earnings and Raises Guidance - GuruFocus
GoodRx (GDRX) Q1 earnings: Taking a look at key metrics versus estimates - MSN
GoodRx Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: GoodRx Q1 2026 revenue exceeds forecasts - Investing.com
GoodRx Holdings, Inc. (GDRX) Reports In-Line Q1 EPS ; Offers Guidance - StreetInsider
Number of shareholders of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
GoodRx Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates - Yahoo Finance
GoodRx (NASDAQ:GDRX) Beats Q1 CY2026 Sales Expectations - Barchart.com
GoodRx Holdings Q1 Adjusted Earnings, Revenue Fall - marketscreener.com
GoodRx (NASDAQ: GDRX) Q1 2026 shifts from Rx volume to Pharma Direct growth - Stock Titan
GoodRx Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
GoodRx Reports First Quarter 2026 Results - Business Wire
3 Promising Penny Stocks With Market Caps Up To $900M - simplywall.st
GoodRx Holdings Inc expected to post earnings of 7 cents a shareEarnings Preview - TradingView
GDRX SEC FilingsGoodrx Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
GoodRx (NASDAQ: GDRX) CAO Thomas Chan reports stock, options and RSUs - Stock Titan
Why GoodRx (GDRX) Stock Is Trading Up Today - Barchart.com
GoodRx offers oral semaglutide starting at $149 per month By Investing.com - Investing.com India
GoodRx expands offerings to now include Ozempic® pill for type 2 diabetes patients - marketscreener.com
GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients - Quantisnow
A new Ozempic pill now starts at $149 a month through GoodRx - Stock Titan
GDRX Forecast, Price Target & Analyst Ratings | GOODRX HOLDINGS INC-CLASS A (NASDAQ:GDRX) - ChartMill
[ARS] GoodRx Holdings, Inc. SEC Filing - Stock Titan
Executive pay, auditor change headline GoodRx (NASDAQ: GDRX) 2026 vote - Stock Titan
What's Going On With GoodRx Stock Thursday? - Sahm
GDRX vs. HQY: Which Stock Is the Better Value Option? - MSN
GoodRx (GDRX) Q2 2024 earnings summary - Quartr
GoodRx won't be participating with TrumpRx: report - MSN
What's going on with GoodRx stock Thursday? - MSN
GoodRx Holdings, Inc. Appoints New Chief Accounting Officer and Files Form 8-K with SEC - Minichart
GoodRx appoints Thomas Chan as chief accounting officer By Investing.com - Investing.com India
GoodRx Names Thomas Chan Chief Accounting Officer - TipRanks
GoodRx appoints Thomas Chan as chief accounting officer - Investing.com
GoodRx names Thomas Chan as Chief Accounting Officer - TradingView
GoodRx (NASDAQ: GDRX) appoints Thomas Chan as new Chief Accounting Officer - Stock Titan
OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy? - The Globe and Mail
GDRX GoodRx Holdings shares climb 4.41 percent after Q4 2025 results despite a minor EPS miss against analyst expectations.Social Trade Signals - Cổng thông tin điện tử tỉnh Tây Ninh
GDRX (GoodRx Holdings Inc.) drops 3.4% today after Q4 2025 EPS narrowly falls short of analyst expectations.Risk Event - Xã Thanh Hà
GoodRx Holdings (GDRX) Sector Leadership | Q4 2025: EPS Misses EstimatesSector Outperform - Cổng thông tin điện tử tỉnh Tây Ninh
Healthcare Technology Stocks Q4 Recap: Benchmarking GoodRx (NASDAQ:GDRX) - Barchart.com
GoodRx Holdings (GDRX) Stock Municipal Bond (Slight Rise) 2026-04-20Crowd Signals - Cổng thông tin điện tử tỉnh Tây Ninh
GoodRx Holdings (GDRX) Stock Trade Ticket (-3.40%) 2026-04-18Stock Community Signals - Cổng thông tin điện tử tỉnh Tây Ninh
GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call - 01net
GoodRx rallies as Wegovy HD rollout targets self-pay market - MSN
Goodrx Holdings Inc Azioni (GDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Goodrx Holdings Inc Azioni (GDRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Spectrum Equity VII, L.P. | 10% Owner |
Oct 15 '25 |
Sale |
4.00 |
23,771 |
95,103 |
0 |
5.58%
2.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):